BIO
BIO
US0905722072
Bio-Rad Laboratories, Inc.
Loading chart...

Company Profile

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Latest News

Related stocks

PODD
PODD • United States
Insulet Corporation
135.28 USD
9.38B USD 1Y -57.4%
GMED
GMED • United States
Globus Medical, Inc.
74.65 USD
10.02B USD 1Y +21.4%
BRKR
BRKR • United States
Bruker Corporation
58.84 USD
8.96B USD 1Y +67.3%
GKOS
GKOS • United States
Glaukos Corporation
165.69 USD
9.77B USD 1Y +84.1%
PEN
PEN • United States
Penumbra, Inc.
319.4 USD
12.58B USD 1Y +22.6%
STE
STE • United States
STERIS plc (Ireland)
214.4 USD
20.9B USD 1Y -13%
HAE
HAE • United States
Haemonetics Corporation
118.69 USD
5.4B USD 1Y +134.3%
ZBH
ZBH • United States
Zimmer Biomet Holdings, Inc.
89.14 USD
17B USD 1Y -9.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
37.8% p.a.
Max Drawdown (5Y)
-72.8%
Sharpe Ratio (5Y)
-0.41
Beta Factor
1.07
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 46.4 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (37.8% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -73.8% in the extended horizon.
ende